Abstract
To the Editor: The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) was presented at the American Heart Association meeting >2 years before its publication.1 At that time, a lot of confusion and uncertainty was created by the press releases. Some authors stated, “In the 825-patient Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT), cardiovascular morbidity and mortality events were reduced by 31%. These events included heart attacks, strokes, deaths, angioplasty, bypass surgery, hospitalizations for severe angina, and heart failure.”2 Other authors seemed to disagree: “There was no difference in the overall …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
